Andrew Hill Fund Sees Vertex Growth Beyond Cystic Fibrosis
The fund says Vertex’s cystic fibrosis cash flow supports investments in kidney disease, pain management and other specialty areas.
Makkler Newsroom · Oct 8, 05:54 PM · 1 min read
Vertex Pharmaceuticals Incorporated VRTX
NASDAQHealth TechnologyUnited States
$538.60-4.02 (-0.74%)
Market closed· · USD · Data may be delayed
- Day's range
- 536.12543.73
- 52-week range
- 412.27568.67
Financial health
– / 5
Analyst view · 32 firms
Buy24 buy · 7 hold · 1 sell
Avg. target $601.36 (+11.7%)
Prices may be delayed and are for informational purposes only - not investment advice.